VitaNova Life Sciences Corporation
VNOV · Industrials · FY2025 filings · Narrow moat ·
On the watchlist
The five investor questions
2022–2025: revenue 120000.00 to 2662105.00, increasing; diluted EPS 0.02 to 0.03, increasing.
Median gross margin 66.2% over 3y, variable.
Median ROIC 30.4%, above the 12% hurdle in 67% of years.
Net debt/EBITDA n/ax, interest coverage 268x.
Owner earnings trend unclear, share count n/a.
Price vs. owner-earnings value range
- Owner earnings (normalized)
- —
- Value range / share
- —
- Conservative high estimate / share
- —
- Recent price
- —
- Price vs. high estimate
- No price data
Conservative range under moat-index@2.0.0: low end 11.1×, high end capped at 18×; 9% discount rate; high-end growth 0% (capped at 4%) using min(5y revenue CAGR, 5y diluted-EPS CAGR), clamped to 0%–4%; maintenance capex uses min(capex, D&A); abstain when D&A is unavailable. This is a disclosed model range, not intrinsic value as fact.
9 years of fundamentals
The business, in plain English
VitaNova Life Sciences Corporation booked $2.7M of revenue in FY2025 in the Industrials sector and kept 59.2% of it as gross profit — a high-margin business by that measure. After every other cost, 32.0% of each revenue dollar reached the bottom line.
It earned 75.8% on invested capital in FY2025, with a median of 30.4% across 3 filed years. The Returns on Capital filter above scores it 88/100.
VNOV's filings don't disclose total debt in a form the methodology can use, so leverage is treated as unmeasured — never assumed to be zero.
The share count rose 614.6% between FY2017 and FY2025 — existing owners have been diluted over the record. Capital Discipline scores it 44/100.
Put together: Returns on Capital is the strongest of the five filters (88/100) and Capital Discipline the weakest (44/100), which is how VNOV lands at 73/100 — a Narrow moat.
This breakdown is generated from the filed numbers and sub-scores above — no outside narrative, no estimates. Where a filing doesn’t disclose an input, the sentence that would need it is omitted instead of guessed.
Gaps in a line mean that item isn’t in VNOV’s filings for that year — the series is never interpolated or estimated. The Table view lists every filed value, including operating and net margins, total debt, and share count.
Moat Score history
Tier changesSame-methodology crossings of the Wide / Narrow / Shallow bars
- Methodology upgraded moat-index@1.2.0tomoat-index@2.0.0 — readings across versions aren’t comparedJul 20, 2026
Scores are logged append-only and never overwritten — this record can’t be backfilled, which is exactly why it’s worth keeping.
Track record
How VitaNova Life Sciences Corporation’s moat rated in each of the years we can reconstruct from its filings — scored only on what was knowable at the time — and what its price and returns did afterward. The score never saw a price; the two are joined only in hindsight, for education, not as a signal.
How to read this: each dot is what the engine would have scored VNOV on that December 31; the line below is its total-return price path (dividends reinvested) in the years since.
Two tracks, one timeline: the score has its own 0–100 scale (top), the price its own 100-based scale (bottom) — never a shared axis. The indexed price path isn't available for this company yet; gaps in the score line are years with no reconstructed rating (see the table for why). The Table view carries every value.
What followed, in the years it rated Wide
In the reconstructed history shown, VNOV did not rate Wide-moat in any year, so there is no wide-moat track record to report. That absence is itself the honest answer — we don’t manufacture a comparison where the rating never earned one.
Industrials context
#56 of 423 scored Industrials companies, ranked by Moat Score.
Nearest peers by Moat Score
- #54CRCT Cricut, Inc.72.7 out of 100, Narrow moatNarrow moat
- #55DPZ Domino’s Pizza, Inc.72.5 out of 100, Narrow moatNarrow moat
- #57AAON AAON, INC.72.4 out of 100, Narrow moatNarrow moat
- #58DHI D.R. Horton, Inc.72.0 out of 100, Narrow moatNarrow moat
Compare VNOV with its nearest peers →All Industrials companies on the Index →
Common questions about VNOV
- Does VitaNova Life Sciences Corporation have an economic moat?
- Based on its FY2025 SEC filings, the Moat Index scores VitaNova Life Sciences Corporation (VNOV) 72.5 out of 100 — a Narrow moat. The five questions behind that score begin at 20% each; if exactly one genuinely lacks data, the other four weights are renormalized and disclosed. revenue and EPS trend 87, pricing power 71, returns on capital 88, balance-sheet safety 73, capital discipline 44.
- How has VNOV's Moat Score changed over time?
- The record logs 8 readings since Jul 17, 2026; the latest reads 72.5 out of 100 (narrow moat). No tier changes on record yet. (A methodology upgrade on Jul 20, 2026 re-based the score; readings across engine versions aren't compared.) The history is append-only — readings are only ever added, never rewritten.